Abarelix

Abarelix

Clinical data
ATC code	L02BX01 (WHO)
Pharmacokinetic data
Protein binding	96–99%
Identifiers
IUPAC name acetyl-D-β-naphthylalanyl- D-4-chlorophenylalanyl-D-3-pyridylalanyl-L-seryl-L- N-methyl- tyrosyl-D-asparagyl-L-leucyl-L-N(e )-isopropyl-lysyl-L-prolyl-D-alanyl-amide
CAS Number	183552-38-7
DrugBank	BTD00051
E number	{{#property:P628}}
ECHA InfoCard	{{#property:P2566}}
Chemical and physical data
Formula	C72H95ClN14O14
Molar mass	1416.06 g/mol

WikiDoc Resources for Abarelix
Articles
Most recent articles on Abarelix Most cited articles on Abarelix Review articles on Abarelix Articles on Abarelix in N Eng J Med, Lancet, BMJ
Media
Powerpoint slides on Abarelix Images of Abarelix Photos of Abarelix Podcasts & MP3s on Abarelix Videos on Abarelix
Evidence Based Medicine
Cochrane Collaboration on Abarelix Bandolier on Abarelix TRIP on Abarelix
Clinical Trials
Ongoing Trials on Abarelix at Clinical Trials.gov Trial results on Abarelix Clinical Trials on Abarelix at Google
Guidelines / Policies / Govt
US National Guidelines Clearinghouse on Abarelix NICE Guidance on Abarelix NHS PRODIGY Guidance FDA on Abarelix CDC on Abarelix
Books
Books on Abarelix
News
Abarelix in the news Be alerted to news on Abarelix News trends on Abarelix
Commentary
Blogs on Abarelix
Definitions
Definitions of Abarelix
Patient Resources / Community
Patient resources on Abarelix Discussion groups on Abarelix Patient Handouts on Abarelix Directions to Hospitals Treating Abarelix Risk calculators and risk factors for Abarelix
Healthcare Provider Resources
Symptoms of Abarelix Causes & Risk Factors for Abarelix Diagnostic studies for Abarelix Treatment of Abarelix
Continuing Medical Education (CME)
CME Programs on Abarelix
International
Abarelix en Espanol Abarelix en Francais
Business
Abarelix in the Marketplace Patents on Abarelix
Experimental / Informatics
List of terms related to Abarelix

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Abarelix is an injectable gonadotropin-releasing hormone antagonist (GnRH antagonist). It is primarily used in oncology to reduce the amount of testosterone made in patients with advanced symptomatic prostate cancer for which no other treatment options are available. It belongs to the family of drugs called Gonadotropin-releasing hormone antagonists.

It is marketed by Speciality European Pharma as Plenaxis. Plenaxis has received marketing authorisation in Germany.

References

Template:WikiDoc Sources